Speaker Information 

Berk Ozdemir

CEO,
Omega CRO, Ankara, Turkiye

Berk Ozdemir, born in Ankara in 1979, graduated from Gazi University, Department of Chemical Engineering, in 2003. He subsequently completed his postgraduate studies in Business Administration and Organization, graduating from Anadolu University’s Health Institutions Management program in 2013. He is currently pursuing undergraduate education in Management Information Systems and Sociology.

Starting his career in 1997, Berk Ozdemir joined Omega CRO, Turkey’s first contract research organization, in 1999. He is a founding member of SAKDER (Association of Contract Research Organizations), established in 2009, and currently serves as the association’s president. He also serves on the board of directors of The European CRO Federation (EUCROF).

As the CEO of Omega CRO, Berk �zdemir is also the founder of Omega Genetik (Omega Genetic Diseases Evaluation Center), Omega �are Home Care Services, HelixLab Clinical Research R&D Laboratory, Bioligo Biotechnology, and Omega-Bio Biotechnology, as well as a managing partner of Synbiyotik Biotechnology. Accordingly, under the leadership of Berk Ozdemir, Omega Group is Turkey’s leading integrated health services provider, operating 8 companies across clinical research (Omega CRO), biotechnology (Omega Bio), genetic diagnostics (Omega Genetik Lab), digital health (Spinex, Omega Care), health technologies (Synbiyotik), laboratory services (Helix Lab), and pharmaceutical logistics (Omega Depo). With 29 years of experience and Top 500 service exporter status, Omega Group provides end-to-end solutions for clinical research and health technology development in Turkey and the region.

Since joining Omega CRO, he has been involved in the design, management, and analysis of more than 1,000 clinical trials. During the COVID-19 pandemic starting in 2020, he led the design, management, and analysis of clinical and observational studies related to the CoronaVac and TURKOVAC vaccines.